Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Geron Corporation

Healthcare US GERN

1.21USD
0.05(4.31%)

Last update at 2026-06-04T20:04:00Z

Day Range

1.171.23
LowHigh

52 Week Range

1.042.01
LowHigh

Fundamentals

  • Previous Close 1.16
  • Market Cap961.35M
  • Volume9823813
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-51.07900M
  • Revenue TTM183.88M
  • Revenue Per Share TTM0.28
  • Gross Profit TTM 179.14M
  • Diluted EPS TTM-0.13

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -85.78200M -174.57200M -184.12700M -141.90100M -116.11200M
Minority interest - - - - -
Net income -85.78200M -174.57200M -184.12700M -141.03300M -120.95200M
Selling general administrative 159.26M 145.73M 69.14M 43.63M 29.66M
Selling and marketing expenses - - 1.03M - -
Gross profit 179.14M 75.74M 0.24M 0.60M 1.39M
Reconciled depreciation 1.20M 1.22M 1.03M 0.87M 0.78M
Ebit -53.12500M -156.06800M -175.81500M -138.55000M -113.99900M
Ebitda -51.92100M -154.84700M -174.78200M -135.01900M -111.58900M
Depreciation and amortization 1.20M 1.22M 1.03M 3.53M 2.41M
Non operating income net other - - - 3.53M 1.63M
Operating income -53.83500M -173.73200M -193.94400M -138.55000M -113.99900M
Other operating expenses 237.72M 250.73M 194.18M 139.15M 115.39M
Interest expense 32.66M 18.50M 8.31M 6.88M 3.74M
Tax provision - - - - -
Interest income 18.12M 19.61M 18.15M 2.53M 0.53M
Net interest income -14.54000M 1.10M 9.84M -4.35300M -3.21300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00000M -0.86800M 4.84M
Total revenue 183.88M 76.99M 0.24M 0.60M 1.39M
Total operating expenses 232.97M 249.47M 194.18M 139.15M 115.39M
Cost of revenue 4.75M 1.26M 123.74M - -
Total other income expense net -31.94700M -0.84000M 9.82M -3.35100M -2.11300M
Discontinued operations - - - - -
Net income from continuing ops -83.50000M -174.57200M -184.12700M -141.90100M -116.11200M
Net income applicable to common shares - - - -141.90100M -116.11200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 570.54M 593.78M 394.08M 190.57M 226.03M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 121.25M 6.91M 4.88M 7.14M 3.12M
Total liab 344.67M 313.46M 146.13M 110.58M 99.62M
Total stockholder equity 225.87M 280.32M 247.95M 80.00M 126.42M
Deferred long term liab - - - - -
Other current liab 80.84M 78.73M 54.07M 44.63M 37.93M
Common stock 0.64M 0.61M 0.55M 0.39M 0.32M
Capital stock 0.64M 0.61M 0.55M 0.39M 0.32M
Retained earnings -1855.84100M -1772.34100M -1597.76900M -1413.64200M -1271.74100M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - 5.39M 4.80M
Cash 79.44M 79.02M 71.14M 57.21M 34.87M
Cash and equivalents - - - - -
Total current liabilities 111.54M 88.30M 108.07M 76.69M 45.52M
Current deferred revenue - - - - -
Net debt 172.13M 42.70M 14.76M -1.45600M 20.13M
Short term debt 19.45M 0.97M 47.84M 21.87M 0.90M
Short long term debt - - 46.89M 20.95M -
Short long term debt total 251.57M 121.72M 85.90M 55.75M 55.00M
Other stockholder equity 2080.80M 2051.79M 1844.99M 1493.47M 1398.01M
Property plant equipment - - - 0.79M 0.65M
Total current assets 520.27M 490.99M 341.35M 180.25M 187.21M
Long term investments 41.29M 94.52M 43.30M 0.00000M 28.65M
Net tangible assets - - - 80.00M 126.42M
Short term investments 280.36M 327.55M 263.68M 115.90M 148.85M
Net receivables 39.23M 38.80M 1.66M 3.14M 1.76M
Long term debt 119.55M 118.48M 35.05M 30.21M 49.83M
Inventory 116.64M 38.71M - -3.14400M -1.39900M
Accounts payable 11.26M 8.60M 6.16M 10.19M 6.69M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.27M 0.26M 0.18M -0.21900M -0.17300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.39M 0.32M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1413.64200M -1271.74100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.10M 4.08M 4.70M 9.54M 4.80M
Deferred long term asset charges - - - - -
Non current assets total 50.27M 102.79M 52.73M 10.33M 38.83M
Capital lease obligations 2.44M 3.24M 3.96M 4.60M 5.17M
Long term debt total - - - 30.21M 49.83M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 107.30M -106.00400M -180.32200M 62.50M 70.56M
Change to liabilities - - - 10.20M 14.56M
Total cashflows from investing activities 107.25M -106.00400M -180.32200M 62.07M 71.95M
Net borrowings 0.00000M 34.57M 29.70M - 24.89M
Total cash from financing activities 2.27M 334.37M 362.02M 87.26M 48.56M
Change to operating activities - - - 1.52M 10.75M
Net income -85.78200M -174.57200M -184.12700M -141.90100M -116.11200M
Change in cash -1.43600M 9.74M 13.93M 21.97M 24.95M
Begin period cash flow 80.88M 71.14M 57.21M 35.23M 10.29M
End period cash flow 79.44M 80.88M 71.14M 57.21M 35.23M
Total cash from operating activities -111.03700M -218.61800M -167.74300M -127.37900M -95.55600M
Issuance of capital stock 0.00000M 140.73M 213.34M 69.92M 20.39M
Depreciation 1.20M 1.22M 1.03M 0.87M 0.78M
Other cashflows from investing activities - - -179.49200M - 1.59M
Dividends paid - - - - -
Change to inventory -77.92200M -37.97100M 0.00000M - -
Change to account receivables -0.37700M -36.89300M 1.49M - -
Sale purchase of stock - - - 17.35M 23.66M
Other cashflows from financing activities 2.27M 159.08M 118.98M 17.35M 28.17M
Change to netincome - - - 8.27M 6.94M
Capital expenditures 0.05M 0.68M 0.83M 0.43M 0.21M
Change receivables - - - - -
Cash flows other operating - - - -4.59700M -3.47200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 21.95M 24.95M
Change in working capital -68.53600M -68.41100M 6.06M 5.03M 10.52M
Stock based compensation 0.09M 31.32M 19.35M 8.00M 8.08M
Other non cash items 41.99M -8.17600M -10.06200M 0.63M 0.98M
Free cash flow -111.08600M -219.29800M -168.57300M -127.81000M -95.76300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GERN
Geron Corporation		 0.05 4.31% 1.21 - - 5.23 4.43 4.15 -9.0637
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

919 East Hillsdale Boulevard, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Dr. John A. Scarlett M.D. Chairman, Pres & CEO 1951
Ms. Olivia Kyusuk Bloom Exec. VP of Fin., CFO & Treasurer 1969
Dr. Andrew J. Grethlein Exec. VP & COO 1964
Ms. Melissa A. Kelly Behrs Exec. VP of Bus. Operations & Chief Alliance Officer 1964
Mr. Anil Kapur Exec. VP of Corp. Strategy & Chief Commercial Officer 1970
Ms. Aron Feingold VP of Investor Relations & Corp. Communications NA
Mr. Stephen N. Rosenfield J.D. Exec. VP, Chief Legal Officer & Corp. Sec. 1950
Ms. Shannon Odam VP of HR NA
Mr. Edward E. Koval Exec. VP & Chief Bus. Officer 1962
Dr. Faye Feller M.D. Exec. VP & Chief Medical Officer 1982

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.